ClinicalTrials.gg
Sign In

Hepatoblastoma clinical trials

The registry lists 82 studies for Hepatoblastoma across more than 10 countries. 17 are recruiting or about to start. 22 of them are mainly about Hepatoblastoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-28.

Get an email when these change. Save the Hepatoblastoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
31
Active, not recruiting
16
Recruiting
16
Status unknown
8
Withdrawn
4
Terminated
4

Phase

Phase 2
33
Phase 1
22
Phase 3
11
Early Phase 1
1
Phase 4
1

Where

United States
54
Puerto Rico
16
Canada
10
China
10
Australia
9
France
7

Who runs them

National Cancer Institute (NCI) (17) · Children's Oncology Group (9) · Emory University (4) · Masonic Cancer Center, University of Minnesota (3) · Memorial Sloan Kettering Cancer Center (3) · Seattle Children's Hospital (3) · Baylor College of Medicine (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2)

What is being tested here

Drugs under test in Hepatoblastoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Melphalan104
Sodium thiosulfate134
Cyclophosphamide104
Fludarabine102
Lenvatinib112
Codrituzumab101
Tegavivint101
Talazoparib101
Temozolomide101
Vorinostat101

Drug classes tested here Alkylating agents 2 open · Tyrosine kinase inhibitors (TKIs) 1 open · Immune checkpoint inhibitors 1 open · Antimetabolites 1 open · PARP inhibitors 1 open

Coming up

3phase 3 studies under way
11studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 16 Hepatoblastoma studies recruiting now, 2 (13%) set no upper age limit and 13 (81%) stop at 75 or younger. 15 (94%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 16
AgeWomenMen
1015 (94%)15 (94%)
1816 (100%)16 (100%)
307 (44%)7 (44%)
404 (25%)4 (25%)
504 (25%)4 (25%)
653 (19%)3 (19%)
753 (19%)3 (19%)
853 (19%)3 (19%)

Across all 82 studies, recruiting or not: 91% stop at 75 or younger and 89% at 65; 98% take children; 0% are for women only and 0% for men only; 1% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hepatoblastoma studies take

Of 18 phase 2 interventional studies under Hepatoblastoma, half reached primary completion within 56 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 256 mo49–85 · 18 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 82. Browse all 82 → or search them.